Published in Biotech Business Week, December 26th, 2005
Revenue for the 9 months ended September 30, 2005 was $12,676,000 compared to $6,409,000 for the 9 months in 2004.
Revenue for both the 3-month and 9-month periods ended September 30, 2005 included Fortical product sales to Upsher-Smith Laboratories (USL) representing launch quantities into distribution channels as well as royalties earned from USL sales following the August 16 product launch.
UGNE's net income for the 9 months ended...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.